Treatment Information

Back

Colon Cancer treatment details. Chemotherapy, Biologic therapy.

University Hospital Gasthuisberg, Leuven, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:4City/State/Province:Leuven
Treatments:Chemotherapy, Biologic therapyHospital:University Hospital Gasthuisberg
Drugs:Journal:Link
Date:Oct 2012

Description:

Patients:
This phase 3 study involved metastatic colorectal carcinoma patients who were divided into two separate treatment groups. Group A included 614 patients, 57.5% male, with a median age of 61 years. Group B had 612 patients, 59.6% male, with a median age of 61 years.

Treatment:
Patients in group A were treated with the chemotherapy combination called FOLFIRI (fluorouracil, leucovorin, and irinotecan) and a placebo.

Patients in group B were treated with the FOLFIRI chemotherapy combination and the biologic therapy agent aflibercept, a VEGF inhibitor that interferes with tumor blood supply.

Toxicities:
The most severe toxicities in group A were of grade 4 and included infection, blood clotting, and neutropenia.

The most severe toxicities in group B were of grade 4 and included stomatitis (inflammation of the lining of the GI tract), hemorrhage, blood clotting, and neutropenia.

Results:
The median overall survival rates for groups A and B were 12.06 and 13.5 months, respectively.

Support:
This study was supported by Sanofi and Regeneron.

Correspondence: Dr. Eric Van Cutsem; email: [email protected]



Back